Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

AI in the life sciences – the good, the bad and the ugly

Posted on November 7th, 2018 by

Pharma R&D

gbu

Everyone in the life science industry – from the C-suite in the boardroom to scientists at the bench – are talking about the potential of AI, especially now they’re starting to see pharma companies using the technology. And we are beginning to see researchers mixing diverse kinds of data together – images, text and numeric data to name a few – to learn from. Continue reading “AI in the life sciences – the good, the bad and the ugly” »

Machine Learning Could Make Drug Discovery Faster, Cheaper, Better

Posted on November 6th, 2018 by

Pharma R&D

pharma machine learning new

The stats on the increasingly high cost (and low success rates) in drug discovery are always jarring. As Phee Waterfield of Binary District Journal reports:

  • Bringing a new drug to market is estimated to cost major pharma firms more than $4 billion
  • The process can take 10-15 years
  • Fewer than 10% actually make it to market

Continue reading “Machine Learning Could Make Drug Discovery Faster, Cheaper, Better” »

How Greater Collaboration and Access to Data can Help Tackle Rare Diseases

Posted on November 1st, 2018 by

Pharma R&D

pharma datathon NEW

It is estimated that 30 million people in the United States alone are living with one of 7,000 rare diseases, this equates to 10% of the population. There is, however, little financial incentive for the pharmaceutical sector to develop new treatments for these diseases because of the small patient population each disease affects. Continue reading “How Greater Collaboration and Access to Data can Help Tackle Rare Diseases” »

Experts Gather for a Pair of Pharma & Biotech Conferences

Posted on October 22nd, 2018 by

Pharma R&D

medicinal chemistry event new

From October 29-30, London will be the site of two important events for the pharma and biotech industries, the 2nd Medicinal Chemistry Summit: Europe and the 2nd Global Pharma R&D Informatics & AI Congress. Presented by Global Engage, the conferences will be co-located at the Radisson Blu Edwardian Heathrow, opening up the opportunity for industry professionals to sample what each has to offer.  Continue reading “Experts Gather for a Pair of Pharma & Biotech Conferences” »

Are Drug-Drug Interactions Today’s Biggest Health Threat?

Posted on October 16th, 2018 by

Pharma R&D

drug interaction new

The use of prescription medicines is sharply on the rise. Over the past decade, the number of adults taking over-the-counter medicines has sunk, while the number of prescription drug users has increased by more than 30 percent. Continue reading “Are Drug-Drug Interactions Today’s Biggest Health Threat?” »

Human Cells + Tech = Accelerated Drug Development and Treatment

Posted on October 16th, 2018 by

Pharma R&D

bioprinting new

Some scientific advancements can be both awe-inspiring and just a little creepy at the same time. In the world of pharma and medicine, this applies to some newer approaches that are melding living cells with high-tech to do some wonderful things. Two such advances, which made the short list for BiopharmaTrend.com’s top trends in pharmaceutical research for 2018, are organs-on-chips and bioprinting. Continue reading “Human Cells + Tech = Accelerated Drug Development and Treatment” »

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 61


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.